Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Portfolio Pulse from
Akero Therapeutics will present new analyses from its Phase 2b HARMONY study at the 75th Annual AASLD The Liver Meeting® 2024. The study showed significant regression of liver fibrosis in over 40% of participants treated with EFX 50mg for 96 weeks, compared to 0% for placebo.
November 15, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics' Phase 2b HARMONY study results show promising liver fibrosis regression in over 40% of participants treated with EFX 50mg, which will be presented at the AASLD 2024 meeting.
The positive results from the Phase 2b HARMONY study, showing significant liver fibrosis regression, are likely to boost investor confidence in Akero Therapeutics. The upcoming presentation at a major conference (AASLD 2024) could further increase visibility and interest in the company's stock.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90